 |
15 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- MK-8808 (rituximab biosimilar) / Merck (MSD)
Trial completion, Enrollment change, Metastases: Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) (clinicaltrials.gov) - Dec 24, 2014
P1, N=7, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=22 --> 7
- || MK-8808 (rituximab biosimilar) / Merck (MSD)
Clinical: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (clinicaltrials.gov) - May 8, 2014
P1, N=100, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=22 --> 7 N=180 --> 100
- ||| MK-8808 (rituximab biosimilar) / Merck (MSD)
Clinical: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (clinicaltrials.gov) - May 8, 2014
P1, N=100, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=180 --> 100 Active, not recruiting --> Completed
- || MK-8808 (rituximab biosimilar) / Merck (MSD)
Clinical: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (clinicaltrials.gov) - Apr 24, 2013
P1, N=180, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- MK-8808 (rituximab biosimilar) / Merck (MSD)
New P3 trial, Metastases: A Study Comparing MK-8808 to MabThera (EUDRACT) - Jan 10, 2013
P3, N=520, Terminated, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- MK-8808 (rituximab biosimilar) / Merck (MSD)
Enrollment closed, Metastases: Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) (clinicaltrials.gov) - Jul 18, 2012
P1, N=22, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting